Ovid Therapeutics Stock Today
| OVID Stock | USD 1.10 0.05 4.76% |
Performance0 of 100
| Odds Of DistressOver 56
|
Ovid Therapeutics is trading at 1.10 as of the 25th of November 2024, a 4.76 percent increase since the beginning of the trading day. The stock's lowest day price was 1.07. Ovid Therapeutics has over 56 % chance of experiencing financial distress in the next 2 years of operation and has generated negative returns for investors over the last 90 days. Equity ratings for Ovid Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of October 2024 and ending today, the 25th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 5th of May 2017 | Category Healthcare | Classification Health Care |
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company was incorporated in 2014 and is headquartered in New York, New York. Ovid Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 71.01 M outstanding shares of which 679.89 K shares are now shorted by private and institutional investors with about 7.01 trading days to cover. More on Ovid Therapeutics
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Ovid Stock Highlights
| President | Dirk Haasner | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsOvid Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Ovid Therapeutics' financial leverage. It provides some insight into what part of Ovid Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Ovid Therapeutics (OVID) is traded on NASDAQ Exchange in USA. It is located in 41 Ninth Avenue, New York, NY, United States, 10001 and employs 25 people. Ovid Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 74.56 M. Ovid Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 71.01 M outstanding shares of which 679.89 K shares are now shorted by private and institutional investors with about 7.01 trading days to cover.
Ovid Therapeutics currently holds about 152.37 M in cash with (45.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.16, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Ovid Therapeutics Probability Of Bankruptcy
Ownership AllocationOvid Therapeutics owns a total of 71.01 Million outstanding shares. Over half of Ovid Therapeutics' outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Ovid Ownership Details
Ovid Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Prosight Management, Lp | 2024-06-30 | 1.1 M | |
| Tls Advisors Llc | 2024-09-30 | 771.5 K | |
| Wells Fargo & Co | 2024-06-30 | 741.6 K | |
| Ubs O'connor Llc | 2024-09-30 | 628.3 K | |
| Northern Trust Corp | 2024-09-30 | 480.2 K | |
| Bridgeway Capital Management, Llc | 2024-09-30 | 309.5 K | |
| Gsa Capital Partners Llp | 2024-09-30 | 260.5 K | |
| Bank Of New York Mellon Corp | 2024-06-30 | 218.2 K | |
| Charles Schwab Investment Management Inc | 2024-09-30 | 161.8 K | |
| Rubric Capital Management Lp | 2024-06-30 | 5.3 M | |
| Madison Avenue Partners, Lp | 2024-06-30 | 4.1 M |
Ovid Therapeutics Historical Income Statement
Ovid Stock Against Markets
Ovid Therapeutics Corporate Management
| Meg Alexander | Chief Officer | Profile | |
| Claude MD | Head RD | Profile | |
| SPHR SHRMSCP | VP Facilities | Profile | |
| Jason MBA | Chief Officer | Profile | |
| Lora Pike | Senior Relations | Profile | |
| Garret Bonney | Investor Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ovid Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For information on how to trade Ovid Stock refer to our How to Trade Ovid Stock guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ovid Therapeutics. If investors know Ovid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ovid Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.46) | Revenue Per Share 0.009 | Quarterly Revenue Growth 0.587 | Return On Assets (0.36) | Return On Equity (0.37) |
The market value of Ovid Therapeutics is measured differently than its book value, which is the value of Ovid that is recorded on the company's balance sheet. Investors also form their own opinion of Ovid Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Ovid Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ovid Therapeutics' market value can be influenced by many factors that don't directly affect Ovid Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ovid Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ovid Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ovid Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.